EPS for Cellectis S.A. (CLLS) Expected At $-0.67 as of March, 11

Cellectis S.A. (NASDAQ:CLLS) Corporate Logo

On March, 11 Cellectis S.A. (NASDAQ:CLLS)’s earnings release is awaited by WallStreet, as reported by Faxor. Analysts forecast $-0.67 EPS. That’s $0.09 up or 11.84 % from 2018’s earnings of $-0.76. 24.07 % negative EPS growth is what analysts predict. $-0.54 EPS was published for previous quarter. The stock decreased 0.65% or $0.11 during the last trading session, hitting $16.93.Cellectis S.A. has volume of 78,583 shares. Since February 12, 2018 CLLS has declined 21.71% and is downtrending. CLLS underperformed by 21.71% the S&P 500.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France.The firm is worth $719.89 million. The firm operates through two divisions, Therapeutics and Plants.Currently it has negative earnings. The Company’s lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia and CLL.

For more Cellectis S.A. (NASDAQ:CLLS) news posted briefly go to: Seekingalpha.com, Seekingalpha.com, Seekingalpha.com, Streetinsider.com or Benzinga.com. The titles are as follows: “A Rough Summer Has Knocked Calyxt Down – Seeking Alpha” posted on October 05, 2018, “Cellectis Is The Technological Leader Of CAR-T With CubiCAR, But Still Not A Buy – Seeking Alpha” on June 20, 2018, “Cellectis: Will Focus On Universal CAR-T Payoff? – Seeking Alpha” with a publish date: May 21, 2018, “Baker Bros. Advisors 13F for Quarter Ended Sept. 30, 2018 – StreetInsider.com” and the last “The Daily Biotech Pulse: Big Miss For Seattle Genetics (NASDAQ:SGEN); Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs – Benzinga” with publication date: February 08, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.